Gene: TBC1D22B
Official Full Name: TBC1 domain family member 22Bprovided by HGNC
Gene Summary: Enables 14-3-3 protein binding activity. Predicted to be active in Golgi apparatus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO13535 | TBC1D22B Knockout cell line (HeLa) | Human | TBC1D22B | 1:3~1:6 | Negative | Online Inquiry |
KO13536 | TBC1D22B Knockout cell line (HCT 116) | Human | TBC1D22B | 1:2~1:4 | Negative | Online Inquiry |
KO13537 | TBC1D22B Knockout cell line (HEK293) | Human | TBC1D22B | 1:3~1:6 | Negative | Online Inquiry |
KO13538 | TBC1D22B Knockout cell line (A549) | Human | TBC1D22B | 1:3~1:4 | Negative | Online Inquiry |
TBC1D22B Gene Knockout Cell Lines are genetically engineered cell models that have undergone targeted gene disruption to eliminate the expression of the TBC1D22B gene. This cell line serves as an essential tool for investigating the biological functions of TBC1D22B, a gene implicated in various cellular processes, including vesicular transport, cell signaling, and immune response regulation. By observing the differences in phenotype and signaling pathways between knockout and wild-type cell lines, researchers can elucidate the specific roles of TBC1D22B in physiological and pathological contexts.
The primary function of these knockout cell lines is to provide a versatile platform for functional assays, drug screening, and pathway analysis. The absence of TBC1D22B allows for the assessment of compensatory mechanisms and the investigation of how the loss of this gene affects cellular behavior, including proliferation, apoptosis, and migration. The targeted knockout is achieved through advanced CRISPR-Cas9 gene-editing technology, ensuring precise alteration while minimizing off-target effects.
In research and clinical settings, TBC1D22B Gene Knockout Cell Lines play a crucial role in advancing our understanding of diseases where TBC1D22B may be involved, such as cancers and autoimmune disorders. They can facilitate the development of therapeutic strategies by enabling scientists to test how cells respond to various treatments lacking TBC1D22B.
One of the standout advantages of using these cell lines is their specificity and reliability compared to traditional biochemical assays or non-targeted knockout approaches. They provide a robust model that accurately reflects the genetic underpinnings of cellular processes, thereby enhancing experimental reproducibility.
For researchers and clinicians dedicated to exploring gene function and disease mechanisms, TBC1D22B Gene Knockout Cell Lines offer unparalleled utility and insight. With our company's extensive expertise in genetic engineering and cell line development, we ensure that our products are thoroughly validated, providing dependable tools that propel scientific discovery forward.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.